Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics

被引：0
作者：
Ghannam, Iman A. Y. [1 ]
Hassan, Rasha M. [2 ]
Abdel-Maksoud, Mohammed S. [2 ]
机构：
[1] Natl Res Ctr, Pharmaceut & Drug Ind Res Inst, Chem Nat & Microbial Prod Dept, Cairo 12622, Egypt
[2] Natl Res Ctr, Pharmaceut & Drug Ind Res Inst, Med & Pharmaceut Chem Dept, PO 12622, Giza, Egypt
来源：
BIOORGANIC CHEMISTRY | 2025年 / 156卷
关键词：
PPARs; Neurodegenerative Disorders; Mitochondrial Biogenesis; Autophagy; Neuroprotection; MODERATE ALZHEIMERS-DISEASE; TRANSGENIC MOUSE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; NF-KAPPA-B; GAMMA AGONIST; PARKINSONS-DISEASE; DELTA AGONIST;
D O I：
10.1016/j.bioorg.2025.108226
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Neurodegenerative disorders are characterized by a continuous neurons loss resulting in a wide range of pathogenesis affecting the motor impairment. Several strategies are outlined for therapeutics of synthetic and natural PPARs agonists in some neurological disorders; Parkinson's disease (PD), Alzheimer's disease (AD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD). The aim of this review is to provide a recent update of the previously reported studies, and reviews dealing with the medicinal chemistry of PPARs and their agonists, and to highlight the outstanding advances in the development of both synthetic compounds including; PPAR alpha agonists (fibrates), PPAR gamma agonists (thiazolidindiones), and PPAR beta/delta agonists either as sole or dual acting PPAR full or pan agonists, in addition to the natural phytochemicals; acids, cannabinoids, and flavonoids for their different neuroprotection effects in the previously mentioned neurodegenerative disorders (PD, AD, MS, ALS, and HD). Moreover, this review reports the diverse pre-clinical and clinical studies of PPARs agonists in the neurodegenerative diseases via cellular, and animal models and human.
引用
收藏
页数：17
相关论文
共 136 条
  • [1] Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P., The global prevalence of dementia: a systematic review and metaanalysis, Alzheimers Dement., 9, pp. 63-75.e62, (2013)
  • [2] Moutinho M., Codocedo J.F., Puntambekar S.S., Landreth G.E., Nuclear receptors as therapeutic targets for neurodegenerative diseases: lost in translation, Annu. Rev. Pharmacol. Toxicol., 59, pp. 237-261, (2019)
  • [3] Willems S., Zaienne D., Merk D., Targeting nuclear receptors in neurodegeneration and neuroinflammation, J. Med. Chem., 64, pp. 9592-9638, (2021)
  • [4] Hussain R., Zubair H., Pursell S., Shahab M., Neurodegenerative diseases: regenerative mechanisms and novel therapeutic approaches, Brain Sci., 8, (2018)
  • [5] Gan L., Cookson M.R., Petrucelli L., La Spada A.R., Converging pathways in neurodegeneration, from genetics to mechanisms, Nat. Neurosci., 21, pp. 1300-1309, (2018)
  • [6] Titus C., Hoque M.T., Bendayan R., PPAR agonists for the treatment of neuroinflammatory diseases, Trends Pharmacol. Sci., 45, pp. 9-23, (2024)
  • [7] Michalik L., Auwerx J., Berger J.P., Chatterjee V.K., Glass C.K., Gonzalez F.J., Grimaldi P.A., Kadowaki T., Lazar M.A., O'Rahilly S., Palmer C.N.A., Plutzky J., Reddy J.K., Spiegelman B.M., Staels B., Wahli W., International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors, Pharmacol. Rev., 58, pp. 726-741, (2006)
  • [8] Li L., Luo Z., Yu H., Feng X., Wang P., Chen J., Pu Y., Zhao Y., He H., Zhong J., Liu D., Zhu Z., Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator–activated receptor-δ activation, Diabetes, 62, pp. 762-774, (2013)
  • [9] Botta M., Audano M., Sahebkar A., Sirtori C.R., Mitro N., Ruscica M., PPAR agonists and metabolic syndrome: an established role?, Int. J. Mol. Sci., 19, (2018)
  • [10] Hassan R.M., Aboutabl M.E., Bozzi M., El-Behairy M.F., El Kerdawy A.M., Sampaolese B., Desiderio C., Vincenzoni F., Sciandra F., Ghannam I.A.Y., Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARα agonists with anti-hyperlipidemic and antioxidant activities: design, synthesis and in vitro/in vivo biological evaluation, Bioorg. Chem., 115, (2021)
12345678910